Today, public healthcare systems are confronted with unprecedented demographic and economic challenges. Europe’s population is ageing, healthcare worker shortages are growing, and more innovative treatments and technologies are entering the market. These factors are collectively driving up healthcare costs per patient and straining traditional reimbursement systems. Similarly, the rapid spread of new diseases – exemplified by the COVID-19 pandemic – necessitates cross-country collaborative approaches, for which existing health infrastructures and governance structures are ill-prepared to manage.
Providing citizens with equal access to quality care is a fundamental shared value among European governments, regulatory agencies, and the European Union. Moreover, health and the economy are inextricably linked. Even before the pandemic, poor health was estimated to cost Europe around $2.7 trillion, on average (Global Burden of Disease, 2016). Public healthcare spending should not be viewed as a cost but rather, as an investment. Our mission at Bax & Company is to ensure the sustainability of the public healthcare systems for the benefit of future generations.
Our mission at Bax & Company is to ensure the sustainability of the public healthcare systems for the benefit of future generations.
What do we do?
Healthcare systems cannot respond to these unprecedented challenges within existing frameworks alone. We bring together stakeholders along the bench-to-bedside pathway to solve these major bottlenecks. Furthermore, our expertise in the reimbursement landscape enables us to support our clients in developing effective strategies that facilitate the adoption of innovative treatments and technologies.
During years of supporting the healthcare sector, Bax & Company has brought to life a number of collaborative EU projects which have mobilised around €30M of funding. Two of our most recent healthcare include MatMed, which focuses on Advanced Materials for Regenerative Medicine and Medical Devices in contact with the human body, and Boost4Health, which supports innovative life science SMEs in its partner regions to launch international collaborations.